iBio has appointed endocrinologist Molly Carr as Chief Medical Officer to lead its global clinical strategy, medical affairs, and regulatory initiatives as the company advances its cardiometabolic pipeline toward late-stage development. Dr. Carr brings over 30 years of clinical, academic, and biopharmaceutical experience, most recently serving as Clinical Head and Associate Vice President of Eli Lilly's Insulin and Glucagon Franchise, where she oversaw the Phase 3 program for efsitora, a once-weekly insulin. Her appointment is a critical step as iBio advances its obesity and cardiometabolic pipeline into the clinic, with programs including IBIO-600 and IBIO-610. As an inducement to her employment, iBio granted Dr. Carr options to purchase 430,000 shares of common stock at an exercise price of $1.40 per share, vesting over four years with accelerated vesting upon a change in control or certain involuntary terminations.
iBio, Inc. Common StockAppointment of experienced CMO and stock option grant signal progress in pipeline
Eli Lilly and Company